IRIS
TISEO, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.137
AS - Asia 11.845
EU - Europa 8.276
SA - Sud America 2.353
AF - Africa 696
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 36.334
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.813
SG - Singapore 5.449
CN - Cina 3.012
BR - Brasile 1.861
IT - Italia 1.766
IE - Irlanda 1.663
SE - Svezia 1.401
HK - Hong Kong 1.146
VN - Vietnam 945
DE - Germania 671
FI - Finlandia 623
NL - Olanda 530
ZA - Sudafrica 465
FR - Francia 279
GB - Regno Unito 279
RU - Federazione Russa 277
IN - India 269
TR - Turchia 227
AR - Argentina 199
AT - Austria 198
CA - Canada 156
UA - Ucraina 142
BD - Bangladesh 137
ID - Indonesia 113
MX - Messico 108
EC - Ecuador 94
PL - Polonia 82
CI - Costa d'Avorio 77
IQ - Iraq 76
CZ - Repubblica Ceca 73
JP - Giappone 72
BE - Belgio 71
ES - Italia 61
PK - Pakistan 61
KR - Corea 52
CO - Colombia 45
MA - Marocco 40
PY - Paraguay 37
CL - Cile 35
UZ - Uzbekistan 35
VE - Venezuela 35
IR - Iran 34
LT - Lituania 26
KE - Kenya 25
TN - Tunisia 25
AZ - Azerbaigian 23
KZ - Kazakistan 20
PE - Perù 20
EG - Egitto 19
JO - Giordania 19
SA - Arabia Saudita 18
RO - Romania 16
UY - Uruguay 16
AU - Australia 15
ET - Etiopia 15
IL - Israele 15
LU - Lussemburgo 14
BG - Bulgaria 13
MY - Malesia 13
NP - Nepal 13
CH - Svizzera 12
PA - Panama 12
AE - Emirati Arabi Uniti 10
AL - Albania 9
BH - Bahrain 9
BO - Bolivia 9
OM - Oman 9
BY - Bielorussia 8
CR - Costa Rica 8
HN - Honduras 8
DO - Repubblica Dominicana 7
SI - Slovenia 7
SN - Senegal 7
TW - Taiwan 7
DK - Danimarca 6
DZ - Algeria 6
PS - Palestinian Territory 6
AM - Armenia 5
GR - Grecia 5
JM - Giamaica 5
KG - Kirghizistan 5
MK - Macedonia 5
PH - Filippine 5
RS - Serbia 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
BB - Barbados 4
HU - Ungheria 4
KW - Kuwait 4
LB - Libano 4
LK - Sri Lanka 4
MD - Moldavia 4
NO - Norvegia 4
PT - Portogallo 4
QA - Qatar 4
SV - El Salvador 4
XK - ???statistics.table.value.countryCode.XK??? 4
BA - Bosnia-Erzegovina 3
CY - Cipro 3
EE - Estonia 3
Totale 36.272
Salva come PNG Salva come JPEG
Città #
Singapore 2.882
Ashburn 1.727
Chandler 1.715
Dublin 1.652
Dallas 1.279
Hong Kong 1.125
Beijing 819
Santa Clara 809
Boardman 589
Parma 467
Johannesburg 431
New York 377
Ann Arbor 363
Ho Chi Minh City 361
Princeton 358
Los Angeles 324
Shanghai 318
Munich 260
Dearborn 256
Hanoi 216
Nanjing 189
Des Moines 178
Helsinki 177
Wilmington 175
Moscow 163
Vienna 161
Hefei 159
São Paulo 152
Columbus 149
Milan 141
Izmir 139
Jacksonville 131
Seattle 102
Bremen 101
Buffalo 100
Bologna 97
The Dalles 95
Jakarta 94
Marseille 93
Jinan 86
Chicago 78
Abidjan 77
Rio de Janeiro 77
San Mateo 74
San Jose 70
Nuremberg 68
Warsaw 67
Turku 63
Shenyang 62
Council Bluffs 60
Nanchang 60
Brussels 59
Redmond 59
Tianjin 59
Tokyo 59
Denver 57
Frankfurt am Main 57
London 57
Guangzhou 55
Kunming 54
Hebei 53
Amsterdam 51
Fremont 50
Brno 49
Montreal 49
Belo Horizonte 48
Changsha 48
Chennai 48
Toronto 47
Brooklyn 45
Rome 45
Haiphong 44
Houston 43
Phoenix 42
Atlanta 41
Poplar 41
Bengaluru 39
Curitiba 39
Modena 39
Pune 39
Norwalk 38
Seoul 37
Stockholm 34
San Francisco 33
Tashkent 32
Da Nang 31
Orem 31
Boston 30
Brasília 30
Mexico City 30
Verona 30
Baghdad 29
Porto Alegre 29
Quito 29
Falls Church 28
Jiaxing 28
Kocaeli 27
Manchester 27
Redondo Beach 27
Dhaka 26
Totale 21.788
Salva come PNG Salva come JPEG
Nome #
LINFOCITI INFILTRANTI IL TUMORE, BAP-1, VEGFR-2 E IGF-1R NEL MESOTELIOMA PLEURICO MALIGNO 244
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 220
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 207
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 205
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 202
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 188
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 185
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 182
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 180
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 177
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 176
227P Sexual dimorphism in immune profile of early and advanced NSCLC 173
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 170
Characterization of gefitinib uptake in NSCLC cell lines 164
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 164
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 164
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 164
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 163
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 162
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 160
Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. 157
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 157
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 157
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 157
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 156
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 155
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 154
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 153
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 150
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 148
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 147
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 147
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 146
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 146
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 142
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 141
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 139
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 139
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 139
Advantages of multidetector row CT with multiplanar reformation in guiding percutaneous lung biopsies. 138
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 137
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 137
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 137
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 136
Neoplasie del polmone in Neoplasie del Distretto Toracico 136
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 135
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 135
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 134
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 134
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 134
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 134
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 133
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 133
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 133
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 132
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 131
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 129
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 129
Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions 129
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 128
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 128
IASLC and WHO 2004 Grading System as Prognostic Factors in 492 Cases of Pulmonary Adenocarcinoma 127
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 127
Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience 127
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 126
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 125
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 125
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 124
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 123
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 123
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 122
Multiple primary malignancies involving lung cancer: a single-center experience 122
SMO mutations confer poor prognosis in malignant pleural mesothelioma 122
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 121
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 121
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 120
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 120
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 119
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 118
Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non small cell lung cancer(NSCLC) and fine needle aspirates from distant metastatic sites. 118
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 118
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 118
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 118
Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer 116
METACHRONOUS AND SYNCHRONOUS OCCURRENCE OF PRIMARY MALIGNANCIES IN PATIENTS WITH RESECTED NON SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE OBSERVATIONAL STUDY 115
Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine 115
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. 115
Semiautomatic analysis on computed tomography in locally advanced or metastatic non-small cell lung cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements. 115
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 114
Expression levels of some antioxidant and epidermal growth factor genes on patients with early stage non small cell lung cancer 114
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 114
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 114
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? 114
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 114
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 113
TUMOR-INFILTRATING LYMPHOCYTES, PDL-1, BAP-1, VEGFR-2 AND IGF-1R EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA 113
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 113
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? 112
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 112
Totale 14.042
Salva come PNG Salva come JPEG
Categoria #
all - tutte 153.836
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 153.836
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021754 0 0 0 0 0 85 71 67 175 75 201 80
2021/20221.834 56 32 60 101 51 34 304 136 82 41 134 803
2022/20236.278 806 675 367 428 518 681 70 410 1.991 28 219 85
2023/20242.925 134 199 90 89 288 652 209 199 127 195 256 487
2024/20259.002 220 570 662 514 913 879 452 376 1.079 913 757 1.667
2025/202612.702 1.715 1.799 2.944 2.197 3.262 785 0 0 0 0 0 0
Totale 37.088